This morning, The Medicines Company (NASDAQ:MDCO) reported that the FDA approved its urinary tract infection treatment Vabomere, a move the drug maker hopes will bolster …
In a research report issued Wednesday, Chardan analyst Gbola Amusa reiterated a Buy rating on shares of The Medicines Company (NASDAQ:MDCO) with a price …
The Medicines Company’s Vabomere – A Solid Option for CarbapenemResistant cUTIs: Oppenheimer
The Medicines Company (NASDAQ:MDCO) announced that the U.S.
Yesterday, at the European Society of Cardiology (ESC) Congress 2017 in Barcelona, The Medicines Company (NASDAQ:MDCO) unveiled positive one-year data from the 501-patient …
U.S.
Might Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) finally be bought?